Benefits and risks associated with β-blocker prophylaxis in noncardiac surgery

American Journal of Health-System Pharmacy

Volumn 67, Issue 7, 2010, Pages 523-530

  White, C Michael ^a   Talati, Ripple ^a   Phung, Olivia J ^a   Baker, William L ^a   Reinhart, Kurt ^a   Sedrakyan, Art ^b   Kluger, Jeffrey ^c   Coleman, Craig I ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c Heart Rhythm Service   (United States)

Author keywords

Bradycardia; Hypotension; Mortality; Myocardial infarction; Myocardial ischemia; Protocols; Stroke; Surgery; Sympatholytic agents; Toxicity

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; METOPROLOL;

ABDOMINAL SURGERY; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; DRUG FATALITY; DRUG MECHANISM; GENETIC POLYMORPHISM; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HYPOTENSION; MORTALITY; NEUROSURGERY; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SPINAL ANESTHESIA; STROKE; UROLOGIC SURGERY; VASCULAR SURGERY;

EID: 77950617399     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp090088     Document Type: Article

References (23)

1. Devereaux PJ, Yang H, Yusuf S et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008; 371:1839-1847.
2. Juul AB, Wetterslev J, Kofoed-Enevoldsen A et al. The diabetic postoperative mortality and morbidity (DIPOM) trial: rationale and design of a multicenter, randomized, placebo-controlled, clinical trial of metoprolol for patients with diabetes mellitus who are undergoing major noncardiac surgery. Am Heart J. 2004; 147:677-683.
3. Zaugg M, Bestmann L, Wacker J et al. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) Study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. Anesthesiobgy. 2007; 107:33-44.
4. Fleischer LA, Eagle KA. Clinical practice: lowering cardiac risk in noncardiac surgery. N Engl J Med. 2001; 345:1677-1682.
5. Bangalore S, Wetterslev J, Pranesh S et al. Perioperative beta-blockers in patients having non-cardiac surgery: a meta-analysis. Lancet. 2008; 372:1962-1976 [Erratum, Lancet. 2009; 373:1764.
6. Wallace A, Layug B, Tateo I et al. Prophylactic atenolol reduces postoperative myocardial ischemia. Anesthesiology. 1998; 88:7-17.
7. Fleisher LA, Beckman JA, Brown KA et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol. 2009; 54:e13-118.
8. Mangano DT, Layug EL, Wallace A et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med. 1996; 335:1713-20.
9. Poldermans D, Boersma E, Bax JJ, for the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group (DECREASE). The effect of bisoprolol on perioperative mortality and myocardial infarction in high risk patients undergoing vascular surgery. N Engl J Med. 1999; 341:1789-1794.
10. Hoeks SE, Scholte OP, Reimer WJ et al. Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. Eur J Vasc Surg. 2007; 33:13-19.
11. Liu SS, McDonald SB. Current issues in spinal anesthesia. Anesthesiology. 2001; 94:888-906.
12. Zaugg M, Schaub MC, Foex P. Myocardial injury and its prevention in the perioperative setting. Br J Anesth. 2004; 93:21-33.
13. Rodgers A, Walker N, Schug S et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ. 2000; 321:1493.
14. Frishman WH. Alpha- and beta-blocking drugs. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular therapeutics manual. 2nd ed. New York: McGraw-Hill; 2004:19-57.
15. Packer M, Bristow MR, Cohn JN, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334:1349-1355.
16. Packer M, Colucci WS, Sackner-Bernstein JD et al. Double-blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation. 1996; 94:2793-2799.
17. Yang H, Baymer K, Butler R et al. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J. 2006; 152:983-990.
18. Hansten PD, Horn JR. The top 100 drug interactions: a guide to patient management. Freeland, WA: H&H Publications; 2008.
19. Werner U, Werner D, Rau R et al. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003; 74:130-137.
20. Marraffa JM, Lang L, Ong G et al. Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphenone. Clin Pharmacol Ther. 2006; 79:282-286.
21. Hamelin BA, Bouayad A, Méthot J et al. Significant interaction between nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 2000; 67:466-477.
22. Lindenauer PK, Pekow P, Wang Kmamidi DK et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005; 353:349-361.
23. Piscione F, Iaccarino G, Galasso G et al. Effects of Ile 164 polymorphism on beta2-adrenergic receptor gene on coronary artery disease. J Am Coll Cardiol. 2008; 52:1381-1388.